![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Catco Reinsurance Opportunities Fund Limited | LSE:CAT | London | Ordinary Share | BMG1961Q3242 | ORD USD0.00013716 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 24.00 | 13.00 | 35.00 | 24.00 | 24.00 | 24.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Unit Inv Tr, Closed-end Mgmt | 6.33M | 5.44M | 3.6440 | 6.59 | 35.84M |
RNS No 5487f CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC 9 June 1999 For Further Information Contact Cambridge Antibody Technology Group plc Dr David Chiswell, Chief Executive Officer Tel: +44 (0) 1763 263233 John Aston, Finance Director Dr David Glover, Medical Director HCC De Facto City/Financial, Sue Charles Tel: +44 (0) 171 496 3300 Trade/Science, Andrew Worsfold D2E7 - FURTHER CLINICAL DATA Melbourn, UK New data on D2E7 from clinical trials conducted by BASF Pharma are being presented today at the EULAR '99 conference. D2E7 is the fully human anti-TNF alpha monoclonal antibody, which was developed in a collaboration between BASF Pharma's Bioresearch Corporation and Cambridge Antibody Technology ("CAT"). The data presented are from a study of D2E7 in combination with methotrexate in 54 patients with active rheumatoid arthritis. The randomised double blind placebo controlled study involved a single injection of D2E7 given either i.v. or s.c. The results demonstrate that D2E7 is both well tolerated and efficacious when given i.v. or s.c. in combination with methotrexate. Notes to editors: TNF alpha TNF alpha is a pro-inflammatory cytokine found in the human body. It is believed to increase tissue damage in inflammatory diseases such as rheumatoid arthritis. CAT CAT is a UK biotechnology company using its proprietary technologies in fully human monoclonal antibodies for drug discovery and drug development. Based in Melbourn, 10 miles south of Cambridge, England, CAT currently employs around 150 people. In March 1997, CAT completed its initial public offering and listing on the London Stock Exchange, raising approximately #41 million. CAT has a world-leading platform technology for rapidly isolating fully human monoclonal antibodies using phage display systems. CAT has an extensive phage display antibody library, currently incorporating around 100 billion distinct antibodies. This library forms the basis for the company's strategy to develop a portfolio of clinical development programmes and for discovering new drug leads using functional genomics. The first two antibody products it developed started clinical trials in 1997, in inflammation and fibrosis. CAT has a number of license and collaborative agreements in place with pharmaceutical and biotechnology companies including: Eli Lilly, Pfizer, BASF Pharma, Genentech, ICOS Corporation, Genetics Institute/BASF Pharma and Wyeth-Ayerst. BASF Pharma BASF Pharma is the label used to designate the global corporate pharmaceutical operations of BASF Aktiengesellschaft with headquarters based at Knoll AG in Ludwigshafen, Germany. In 1998, BASF Pharma sales amounted to DM4.51 billion, representing an increase of 10 per cent over the preceding year. The work-force numbers more than 13,000. END MSCBGGBLBGGCCCC
1 Year Catco Reinsurance Opport... Chart |
1 Month Catco Reinsurance Opport... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions